



# Test Definition: MTXSG

Methotrexate Post Glucarpidase, Serum

## Overview

### Useful For

Monitoring methotrexate concentrations post-glucarpidase therapy

Documenting failure to respond that may be due to noncompliance

Guiding dosage adjustments in patients with kidney failure

### Method Name

Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)

### NY State Available

Yes

## Specimen

### Specimen Type

Serum

### Shipping Instructions

Ship specimen in amber vial to protect from light.

### Specimen Required

**Supplies:** Amber Frosted Tube, 5 mL (T915)

**Collection Container/Tube:**

**Preferred:** Red top

**Acceptable:** Serum gel

**Submission Container/Tube:** Amber vial

**Specimen Volume:** 1 mL serum

**Collection Instructions:** Within 2 hours of collection, centrifuge and aliquot serum into an amber vial.

### Forms

If not ordering electronically, complete, print, and send a [Therapeutics Test Request](#) (T831) with the specimen.

### Specimen Minimum Volume

Serum: 0.5 mL

### Reject Due To

Gross hemolysis	OK
-----------------	----

Gross lipemia	OK
Gross icterus	OK
Exposed to light >24 hours	Reject

## Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Serum	Refrigerated (preferred)	7 days	LIGHT PROTECTED
	Ambient	7 days	LIGHT PROTECTED
	Frozen	14 days	LIGHT PROTECTED

## Clinical & Interpretive

### Clinical Information

Methotrexate (MTX) is a folate antimetabolite that reversibly inhibits dihydrofolate reductase. MTX is used alone or in combination with other agents to treat a variety of cancers (ie, breast, leukemia, lymphoma, head and neck, lung, and sarcomas). Administration of intravenous high-dose MTX (ie, 1-15 g/m<sup>2</sup>) occurs at different intervals in treatments and depends on the regimen being used. Therapy is guided by measurement of serum concentration: 24 hours after dosage, the serum concentration should be less than 10 mcmol/L; 48 hours after therapy, concentration should be less than 1 mcmol/L; and 72 hours after dosage, the concentration should be less than 0.1 mcmol/L or less than 0.05 mcmol/L, depending on clinical protocol. MTX can also be used at lower doses (ie, a single dose of 5-15 mg/wk) to treat patients with rheumatoid arthritis and severe psoriasis. In adults, oral absorption appears to be dose dependent. Peak serum concentrations are reached within 1 to 3 hours after oral dosing and 0.5 to 1 hour after intramuscular injection. Protein binding is approximately 50%. Volume of distribution is 0.4 to 0.8 L/kg. Elimination is concentration dependent with an apparent elimination half-life of 3 to 10 hours for patients on low dose therapy (<30 mg/m<sup>2</sup>) compared to 8 to 15 hours for patients on high doses of MTX.

### Reference Values

Nontoxic drug concentration after 72 hours: <0.1 mcmol/L

### Interpretation

Following a 4- to 6-hour intravenous infusion of methotrexate, postinfusion concentrations greater than the following indicate an increased risk of toxicity if conventional low-dose leucovorin rescue is given:

- 24-hour postinfusion concentration: 5.0 to 10.0 mcmol/L
- 48-hour postinfusion concentration: 0.5 to 1.0 mcmol/L
- 72-hour postinfusion concentration: 0.1 mcmol/L

### Cautions

The specimen must be protected from light.

### Clinical Reference

1. Cadman EC, Durivage HJ. Cancer chemotherapy: alkylating agents. In: Wilson JD, Braunwald E, Isselbacher KJ, eds. Harrison's Principles of Internal Medicine. 12th ed. McGraw-Hill Book Company; 1991:1592-1594

2. Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, eds. Harrison's Principles of Internal Medicine. 20th ed. McGraw-Hill Education; 2018
3. Rifai N, Horvath AR, Wittwer CT. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 6th ed. Elsevier; 2017
4. Voraxaze (Glucarpidase). Package insert. BTG International Inc; 2012

## Performance

### Method Description

The serum sample is diluted in a methanol-containing internal standard. The protein precipitate is mixed and centrifuged, and a portion of the supernatant is diluted with mobile phase for detection by tandem mass spectrometry.(Unpublished Mayo method)

### PDF Report

No

### Day(s) Performed

Monday through Sunday

### Report Available

Same day/1 day

### Specimen Retention Time

14 days

### Performing Laboratory Location

Mayo Clinic Laboratories - Rochester Superior Drive

## Fees & Codes

### Fees

- Authorized users can sign in to [Test Prices](#) for detailed fee information.
- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

### Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

### CPT Code Information

80204

### LOINC® Information

# Test Definition: MTXSG

Methotrexate Post Glucarpidase, Serum

Test ID	Test Order Name	Order LOINC® Value
MTXSG	Methotrexate Post Glucarpidase, S	51602-1

Result ID	Test Result Name	Result LOINC® Value
62580	Methotrexate Post Glucarpidase, S	51602-1